Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil

European Journal of Clinical Pharmacology

Volumn 64, Issue 7, 2008, Pages 673-681

  Possuelo, L G ^a,b   Castelan, J A ^c,d   De Brito, T C ^a   Ribeiro, A W ^a   Cafrune, P I ^a,b   Picon, P D ^e   Santos, A R ^f   Teixeira, R L F ^f   Gregianini, T S ^a   Hutz, M H ^b   Rossetti, M L R ^a,c   Zaha, A ^g  

^a Fundacao Estadual de Producao e Pesquisa em Saude   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^d Laboratório Exame   (Brazil)

^e Partenon Sanatorium Hospital   (Brazil)

^f INSTITUTO OSWALDO CRUZ   (Brazil)

^g Centro de Biotecnologia   (Brazil)

Author keywords

Genotyping; Hepatotoxicity; Isoniazid; N acetyltransferase 2; Tuberculosis

Indexed keywords

ACYLTRANSFERASE; ISONIAZID; N ACYLTRANSFERASE 2; PYRAZINAMIDE; RIFAMPICIN;

ACETYLATION; ADULT; AGED; ARTICLE; BRAZIL; CONTROLLED STUDY; GASTROINTESTINAL SYMPTOM; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIVER TOXICITY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUBERCULOSIS;

ACETYLATION; ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; BASE SEQUENCE; BRAZIL; COHORT STUDIES; DNA PRIMERS; LIVER; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; TUBERCULOSIS;

EID: 44449178208     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-008-0484-8     Document Type: Article

References (38)

1. Brasil (2002) Guia de Vigilância Epidemiológica, 1st edn. Fundação Nacional de Saúde/Funasa, Brasília
2. Ingelman-Sundberg M (2001) Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 250:186-200
3. Lundkvist J, Jonsson B (2004) Pharmacoeconomics of adverse drug reactions. Fundam Clin Pharmacol 18:275-280
4. Pande JN, Singh SP, Khilnani GC, Khilnani S, Tandon RK (1996) Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 51:132-136
5. Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, Pitchenik AE (1998) Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 157:1871-1876
6. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D (2003) Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 167:1472-1477
7. Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R, Ito M, Yamamoto Y, Ogura T, Maeda K et al. (2000) Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 4:256-261
8. Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, Chang FY, Lee SD (2002) Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35:883-889
9. Vuilleumier N, Rossier MF, Chiappe A, Degoumois F, Dayer P, Mermillod B, Nicod L, Desmeules J, Hochstrasser D (2006) CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 62:423-429
10. Higuchi N, Tahara N, Yanagihara K, Fukushima K, Suyama N, Inoue Y, Miyazaki Y et al. (2007) NAT2*6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis. World J Gastroenterol 13:6003-6008
11. Hughes HB, Biehl JP, Jones AP, Schimdt LH (1954) Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Tuberc 70:266-273
12. Evans DAP, White TA (1964) Human acetylation polymorphism. J Lab Clin Med 63:394-401
13. Weber WW, Hein DW (1979) Clinical Pharmacokinetics of isoniazid. Clin Pharmacokinet 4:401-422
14. Mitchell JR, Thorgeisson UP, Black M et al. (1975) Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydralazine metabolites. Clin Pharmacol Ther 18:70-79
15. Lin HJ, Han CH, Lin BK, Hardy S (1993) Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, Blacks, Hispanics and Whites: application to metabolic epidemiology. Am J Hum Genet 52:827-834
16. Doll MA, Fretland AJ, Deitz AC, Hein DW (1995) Determination of human NAT2 acetylator genotype by restriction fragment length polymorphism and allele specific amplification. Anal Biochem 231:412-420
17. Cho HJ, Koh WJ, Ryu YJ, Ki CS, Nam MH, Kim JW, Lee SY (2007) Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis 87:551-556
18. Sarma GR, Immanuel C, Kailasan S, Narayana ASL, Venkatesan P (1986) Rifanpin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifanpin. Am Rev Respir Dis 133:1072-1075
19. Singh J, Garg PK, Thakur VS, Tandon RK (1995) Antitubercular treatment induced hepatotoxicity: does acetylator status matter? Indian J Physiol Pharmacol 39:43-46
20. Parthasarathy R, Sarma GR, Janardhanam B, Ramachandran P, Santha T, Sivasubramanian S, Somasundaram PR, Tripathy SP (1986) Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 67:99-108
21. Secretaria Estadual da Saúde (2001) Norma Técnica da política de Controle da Tuberculose. Rio Grande do Sul, Porto Alegre
22. Mayfield D, McLeod G, Hall P (1974) The CAGE questionnaire: validation of a new alcoholism screening instrument. Am J Psychiatry 131:1121
23. Castelo Filho A, Kritski AL, Barreto AW, Lemos ACM, Neto AR, Guimarães CA, Silva CL (2004) II Consenso Brasileiro de Tuberculose: Diretrizes Brasileiras para Tuberculose. J Bras Pneumol 30 Suppl 1
24. Bénichou C (1990) Criteria of drug-induced liver disorders:report of an international concensus meeting. J Hepatol 11:272-276
25. Muller AS, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215
26. Teixeira RL, Miranda AB, Pacheco AG, Lopes MQ, Fonseca-Costa J, Rabahi MF, Melo HM et al. (2007) Genetic profile of the arylamine N-acetyltransferase 2 coding gene among individuals from two different regions of Brazil. Mutat Res 624:31-40
27. Long JC, Willians RC, Urbanek M (1995) An E-M algorithm and testing strategy for multiple-locus haplotypes. Am J Hum Genet 56:799-810
28. Long JC (1999) Multiple locus haplotype analysis, version 2.0. Software and documentation distributed by the autor. Section on population genetics and linkage. Laboratory of Neurogenetics (NIAAA), National Institute of Health, Bethesda
29. Feterson RJ, Goldman G, Long JC (1999) Effects of worldwide population subdivision on ALDH2 linkage disequilibrium. Genome Res 9:844-852
30. Gurumurthy P, Krishnamurthy MS, Nasareth O, Parthasarthy R, Samara GR, Somasundaran PR (1984) Lack of relationship between hepatotoxicity and acetylator phenotype in three thousand south Indian patients during treatment with isoniazid for tuberculosis. Am Rev Respir Dis 129:58-61
31. Fernandez-Villar A, Sopena B, Fernandez-Villar J, Vazquez-Gallardo R, Ulloa F, Leiro V, Mosteiro M, Pineiro L (2004) The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 8:1499-1505
32. Huang YS (2007) Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury. Expert Opin Drug Metab Toxicol 3:1-8
33. Thomas BH, Wong LT, Zeitz W, Solomonarj G (1981) Isoniazid metabolism in the rabbit, and the effect of rifampin pretreatment. Res Commun Chem Pathol Pharmacol 33:235-247
34. Agundez JAG, Martinez C, Oliveira M, Ledesma MC, Ladero JM, Benitez J (1994) Molecular analysis of the arylamine N-acetyltransferase polymorphism in a Spanish population. Clin Pharmacol Ther 56:202-209
35. Baillet G, Santos MR, Alfaro EL, Dipierri JE, Demarchi DA, Carnese FR, Bianchi NO (2007) Allele and genotype frequencies of metabolic genes in Native Americans from Argentina and Paraguay. Mutat Res 627:171-177
36. Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SDJ (2003) Color and genomic ancestry in Brazilians. Proc Natl Acad Sci USA 63:623-628
37. Salzano FM, Freire-Maia N (1970) Problems in human biology. A study of Brazilian populations. Wayne State University Press, Detroit
38. Hiratsuka M (2002) Development of simplified and rapid detection assay for genetic polymorphisms influencing drug response and its clinical applications. Yakugaku Zasshi 122:451-463